Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Increased expression of c-Jun in nonalcoholic fatty liver disease.

Dorn C, Engelmann JC, Saugspier M, Koch A, Hartmann A, Müller M, Spang R, Bosserhoff A, Hellerbrand C.

Lab Invest. 2014 Apr;94(4):394-408. doi: 10.1038/labinvest.2014.3. Epub 2014 Feb 3.

2.

Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet.

Wang C, Cui Y, Li C, Zhang Y, Xu S, Li X, Li H, Zhang X.

Lipids Health Dis. 2013 Nov 4;12:165. doi: 10.1186/1476-511X-12-165.

4.

Fructose as a key player in the development of fatty liver disease.

Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H.

World J Gastroenterol. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166. Review.

5.

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.

Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN.

Hepatology. 2013 Jan;57(1):81-92. doi: 10.1002/hep.25789.

6.

A novel cystine based antioxidant attenuates oxidative stress and hepatic steatosis in diet-induced obese mice.

Sinha-Hikim I, Sinha-Hikim AP, Shen R, Kim HJ, French SW, Vaziri ND, Crum AC, Rajavashisth TB, Norris KC.

Exp Mol Pathol. 2011 Aug;91(1):419-28. doi: 10.1016/j.yexmp.2011.04.009. Epub 2011 May 3. Erratum in: Exp Mol Pathol. 2012 Oct;93(2):282. Vaziri, Nosratola D [corrected to Vaziri, Nosratola D]; Crum, Albert [corrected to Crum, Albert C]. Exp Mol Pathol. 2012 Oct;93(2):281. Kim, H [corrected to Kim, Hyun Ju].

7.

Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.

Gaemers IC, Stallen JM, Kunne C, Wallner C, van Werven J, Nederveen A, Lamers WH.

Biochim Biophys Acta. 2011 Apr;1812(4):447-58. doi: 10.1016/j.bbadis.2011.01.003. Epub 2011 Jan 7.

8.

High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.

Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ.

Hepatology. 2010 Sep;52(3):934-44. doi: 10.1002/hep.23797.

9.

A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance.

Adkins Y, Schie IW, Fedor D, Reddy A, Nguyen S, Zhou P, Kelley DS, Wu J.

Lab Invest. 2013 Dec;93(12):1313-22. doi: 10.1038/labinvest.2013.123. Epub 2013 Oct 21.

10.

Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.

Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, Lyon CJ, Pratico D, Finegold MJ, Wong ST, Webb P, Baxter JD, Moore DD, Hsueh WA.

Hepatology. 2010 Dec;52(6):2001-11. doi: 10.1002/hep.23941. Epub 2010 Oct 11.

11.

Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.

Jump DB, Depner CM, Tripathy S, Lytle KA.

Adv Nutr. 2015 Nov 13;6(6):694-702. doi: 10.3945/an.115.009423. Print 2015 Nov. Review.

12.

Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.

Larter CZ, Yeh MM, Haigh WG, Van Rooyen DM, Brooling J, Heydet D, Nolan CJ, Teoh NC, Farrell GC.

Obesity (Silver Spring). 2013 Jun;21(6):1189-99. doi: 10.1002/oby.20123. Epub 2013 May 10.

13.

Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.

Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-Sverdlov R, Hofker MH.

Hepatology. 2008 Aug;48(2):474-86. doi: 10.1002/hep.22363.

PMID:
18666236
14.
15.

Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice.

Subramanian S, Goodspeed L, Wang S, Kim J, Zeng L, Ioannou GN, Haigh WG, Yeh MM, Kowdley KV, O'Brien KD, Pennathur S, Chait A.

J Lipid Res. 2011 Sep;52(9):1626-35. doi: 10.1194/jlr.M016246. Epub 2011 Jun 20.

16.

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Lytle KA, Wong CP, Jump DB.

PLoS One. 2017 Apr 19;12(4):e0173376. doi: 10.1371/journal.pone.0173376. eCollection 2017.

17.

Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice.

Haque JA, McMahan RS, Campbell JS, Shimizu-Albergine M, Wilson AM, Botta D, Bammler TK, Beyer RP, Montine TJ, Yeh MM, Kavanagh TJ, Fausto N.

Lab Invest. 2010 Dec;90(12):1704-17. doi: 10.1038/labinvest.2010.112. Epub 2010 Jun 14.

18.

Effect of chronic psychosocial stress on nonalcoholic steatohepatitis in mice.

Czech B, Neumann ID, Müller M, Reber SO, Hellerbrand C.

Int J Clin Exp Pathol. 2013 Jul 15;6(8):1585-93. Print 2013.

19.

Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.

Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, Wright JK, Matrisian LM, Brown HA.

PLoS One. 2011;6(8):e22775. doi: 10.1371/journal.pone.0022775. Epub 2011 Aug 9.

20.

Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis.

Handa P, Maliken BD, Nelson JE, Morgan-Stevenson V, Messner DJ, Dhillon BK, Klintworth HM, Beauchamp M, Yeh MM, Elfers CT, Roth CL, Kowdley KV.

Hepatology. 2014 Jul;60(1):133-45. doi: 10.1002/hep.26946. Epub 2014 May 27.

PMID:
24464605

Supplemental Content

Support Center